NASDAQ$IMMX
Immix Biopharma Inc · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Immix Biopharma reported Q1 2026 with no product revenue and a net loss of $10.1M ($0.18 per share) on NexCAR pipeline spend.
Immix had no product revenue in Q1 2026. Operating expenses were $10.8 million (R&D $6.0M, G&A $4.8M); net loss was $10.1 million ($0.18 per share) versus $4.5 million. Recent private placements and public offerings strengthened liquidity for NexCAR clinical programs.
- No product revenue; opex $10.8M.
- Net loss $(10.1)M; EPS $(0.18).
- R&D $6.0M on cell therapy platform.
- September 2025 private placement ~$9.3M gross.
- Pre-commercial with rising burn.
Headline financials
Revenue & EPS history
Immix Biopharma · Revenue · Quarterly
$20M
Forward guidance
Filings focus on NexCAR clinical milestones and cash runway rather than revenue guidance.
Tailwinds
- Capital raises extend runway.
- Focused R&D on CAR-T platform.
Headwinds
- No revenue; losses increasing with trials.
- Clinical and regulatory execution risk.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2026
-2.1%
Avg return
Earnings day
+1.2%
Avg return
5 days after
+13.0%
Avg return
30 days after
24%
5 / 21 earnings
Positive
+11.3%
Q2 2021
Best reaction
-11.3%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -7.8% | +3.0% | -23.4% | |
| Q4 2025 | +4.2% | +0.1% | +14.9% | |
| Q3 2025 | +2.5% | +14.6% | +95.2% | |
| Q4 2024 | +0.0% | -2.2% | -4.3% | |
| Q2 2025 | -2.6% | -8.4% | -9.2% | |
| Q1 2025 | -1.0% | -6.6% | +11.8% | |
| Q3 2024 | -11.3% | -10.2% | +20.3% | |
| Q2 2024 | -4.6% | -2.6% | -4.6% | |
| Q1 2024 | -2.7% | -1.8% | -9.4% | |
| Q4 2023 | -4.9% | -0.3% | -30.6% | |
| Q3 2023 | +5.0% | +4.1% | -0.5% | |
| Q2 2023 | -3.7% | -6.8% | +37.4% | |
| Q1 2023 | -5.9% | -19.2% | -9.1% | |
| Q4 2022 | -2.2% | -0.5% | +1.1% | |
| Q3 2021 | -8.6% | +25.6% | +69.5% | |
| Q3 2022 | -8.6% | +25.6% | +69.5% | |
| Q2 2022 | -4.9% | -7.7% | -26.8% | |
| Q1 2021 | -5.0% | -7.1% | +73.6% | |
| Q1 2022 | -5.0% | -7.1% | +73.6% | |
| Q4 2021 | +11.3% | +16.4% | -37.6% | |
| Q2 2021 | +11.3% | +16.4% | -37.6% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro